Full Press Release Details
| Dr. Reddy's Laboratories Ltd. | |
| 8-2-337, Road No. 3, Banjara Hills, | |
| Hyderabad - 500 034, Telangana, | |
| India. | |
| CIN: L85195TG1984PLC004507 | |
| Tel : +91 40 4900 2900 | |
| Fax : +91 40 4900 2999 | |
| Email : mail@drreddys.com | |
| www.drreddys.com |
| Corporate Relationship Department | National Stock Exchange of India Ltd. | |
| BSE Limited | "Exchange Plaza" | |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), | |
| Mumbai - 400 001 | Mumbai - 400 051 | |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ | |
| 22722037 / 22722039 | 26598238 | |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on
"Promius Pharma, LLC. (a wholly owned subsidiary of Dr. Reddy's Laboratories Ltd.) announces the sale and assignment
of the US rights for its marketed dermatology brands to Encore Dermatology"
This is for your information and record.
Assistant Company Secretary
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
| DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | Investor relationS | Media relationS |
| AMIT AGARWAL amita@drreddys.com (PH: +91-40-4900 2135) | MITALI SARKAR mitali.sarkar@drreddys.com (PH: +91-40-4900 2121) |
Pharma, LLC. (a wholly owned subsidiary of Dr. Reddy's
Laboratories Ltd.) announces the sale and assignment
US rights for its marketed dermatology brands to Encore Dermatology
Hyderabad, India and Princeton, NJ, USA. April 02, 2019 - Dr.
Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as
"Dr. Reddy's"), through its wholly owned subsidiary Promius Pharma, LLC, announces the sale of its rights for
SERNIVO (betamethasone dipropionate) Spray, 0.05% and assignment of its rights to market and distribute, PROMISEB
Topical Cream and TRIANEX 0.05% (Triamcinolone Acetonide Ointment, USP) in the United States, to Encore
Under the terms of the agreement, Promius Pharma is eligible
to receive an upfront payment and future milestone payments contingent upon achievement of certain commercial objectives.
"This is in line with our renewed strategy to enable
us achieve self-sustainability and profitable growth for each of our businesses," said G.V. Prasad, Co-Chairman and CEO,
"We are confident in Encore's ability to realize
the full potential of the enlisted products. We look forward to working with Encore to ensure a smooth transition of these brands
and to ensure they are able to quickly deliver these products to providers and patients." says Anil Namboodiripad, Ph.D.,
Senior Vice President, Proprietary Products, and President, Promius Pharma.
About Dr. Reddy's: Dr. Reddy's
Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable
and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients,
Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs,
custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are
gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets
across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information,
log on to: www.drreddys.com
About Promius Pharma LLC: Promius Pharma is
a wholly-owned subsidiary of Dr. Reddy's Laboratories, one of the largest and most respected pharmaceutical companies in
the world. Promius Pharma is committed to bringing new products to market that meet patients' needs. For more information,
log on to: www.promiuspharma.com.
About Encore Dermatology: Headquartered in
Malvern, Pennsylvania, Encore Dermatology, Inc. is a privately held fully-integrated dermatology company with a mission committed
to delivering innovative prescription therapies and medical devices to dermatologists focusing on customer service and improving
the quality-of-life of patients. For more information, log on to: www.encorederm.com
Disclaimer: This press release may include
statements of future expectations and other forward-looking statements that are based on the management's current views
and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to
differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason
of context, the words "may", "will", "should", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "potential", or "continue"
and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from
those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets,
credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events
(ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes
in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization
, including related integration issues.
The company assumes no obligation to update any information